Navigation Links
FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
Date:11/20/2007

HENDERSON, Nev., Nov. 20 /PRNewswire/ -- FDA spokesman, Brad Swezey, affirmed to the Wall Street Journal (WSJ) yesterday that the FDA had not received any reports of patient injuries or adverse effects related to use of the eyelash product the agency seized last Friday.

According to its November 16, 2007, news release, the FDA seized an eyelash product (not made by Athena Cosmetics) because the agency had concerns that an ingredient in the product, bimatoprost, could possibly have deleterious side effects if it were improperly used in the eye with a medication used to treat glaucoma that also contains bimatoprost. As affirmed by Mr. Swezey in a November 19th WSJ article, the FDA did not seize the eyelash product because the FDA or the company that made the product had received reports of any of the serious side effects listed in the FDA's news release.

The FDA's action has created some public concern about the safety of similar eyelash products sold by Athena Cosmetics, Inc. and other companies. Athena Cosmetics wants to assure its customers that, as confirmed by the FDA for the product it seized, there have been no reports of patient injuries or significant adverse effects from thousands of satisfied RevitaLash(R) customers. To the contrary, only a very small number of RevitaLash(R) consumers have reported minor, temporary side effects such as irritation or redness. In addition, the safety of RevitaLash(R) has been tested in two clinical tests conducted by a reputable research laboratory. No adverse reactions were observed in either clinical study of RevitaLash(R).

RevitaLash(R) was developed by an ophthalmologist, Dr. Michael Brinkenhoff, the founder of Athena Cosmetics. As a practicing physician, Dr. Brinkenhoff formulated RevitaLash(R) with safety as the highest priority. Thousands of happy and satisfied customers have safely used RevitaLash(R) to enhance the beauty of their eyelashes. While Athena Cosmetics is confident that RevitaLash(R) is safe, because of possible public concern over bimatoprost created by the FDA's news release, we have decided to stop selling the current formulation of RevitaLash(R). Fortunately, we had been developing new formulations as part of our ongoing commitment to product excellence and customer satisfaction. To minimize disruption to our loyal customers we will accelerate the launch of our reformulated RevitaLash(R) and are now targeting a mid-December launch. We are excited about our new and improved RevitaLash(R) and remain committed to giving our customers the best -- and safest -- product possible.


'/>"/>
SOURCE Athena Cosmetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
2. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
3. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
4. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
5. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
6. OTC Anti-Aging Products: Hype or Hope?
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
11. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)...  Recently Zymo Research announced an exclusive license ... Horvath,s Clock. Based on this technology, Zymo Research ... academic and biopharma scientific researchers to determine the ... sperm. The service quantifies changes in ... chronological age following drug treatments and identifies disease ...
(Date:12/5/2016)... , Dec. 5, 2016  BD (Becton, Dickinson and ... medical technology company, will demonstrate an enhanced technology platform ... technologies, including the company,s leading Pyxis™ and Alaris™ systems, ... (ASHP) 2016 Midyear Meeting being held in ... While national data show that approximately 68 percent ...
(Date:12/5/2016)... 5, 2016 Research and Markets has announced ... Test Market Size, Share, Development, Growth and Demand Forecast to 2022" ... ... female fertility and pregnancy rapid test market is expected to grow ... and pregnancy rapid test market is witnessing high growth, due to ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... 2016 , ... For many years, Andrew G. Zubinas has accumulated ... beauty of the Lithuanian language and its poetry inspired him in writing ... lyrically explores all aspects of a living, breathing forest where nothing ever stays the ...
(Date:12/5/2016)... ... December 05, 2016 , ... T.E.N., ... that nominations will be accepted from December 5, 2016 through March 3, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ®, a ... design firm kathy ireland® Worldwide for five additional years, announced by Kevin Fick, ... exclusive licensing agreement three years ago to design and develop the kathy ireland® ...
(Date:12/5/2016)... York, NY (PRWEB) , ... December 05, 2016 ... ... companies to use a patent-pending blend of L-Citrulline and glutathione to enhance production ... Blend, a combination that studies have shown to produce NO twice as effectively ...
(Date:12/5/2016)... Nashville, Tennessee (PRWEB) , ... ... ... leader in strategic interoperability, today announced that the company will provide alerting ... platform. CIHIE has been recently awarded $1.7 million in federal funds as ...
Breaking Medicine News(10 mins):